How does the new drug cabozantinib treat advanced kidney cancer?

The new drug cabozantinib has shown significant efficacy in the treatment of advanced renal cancer. Cabozantinib, a multi-target tyrosine kinase inhibitor, has shown excellent results in the treatment of advanced renal cancer. According to relevant studies, patients treated with cabozantinib have significantly prolonged progression-free survival (PFS) and overall survival (OS). For example, in one phase 3 clinical trial, patients treated with cabozantinib had longer PFS than those in the control group, meaning tumor growth and spread were more effectively controlled.

Cabozantinib has shown superior results in the treatment of advanced kidney cancer compared with traditional standard treatments, such as everolimus. Research data shows that cabozantinib is superior to everolimus in prolonging PFS, OS and improving objective response rate (ORR). In addition, cabozantinib can significantly reduce tumor volume, providing a better treatment option for patients with advanced kidney cancer.

In recent years, combination therapy with cabozantinib and other drugs has also achieved impressive results in the treatment of advanced renal cancer. For example, the innovative triple therapy of cabozantinib combined with Nivolumab and Ipilimumab has significantly reduced the risk of disease progression or death in patients with advanced kidney cancer. This combination therapy enhances the therapeutic effect by acting on multiple targets simultaneously, resulting in longer survival for patients.

Although cabozantinib is effective in treating advanced renal cancer, patients may also experience some side effects during use, such as diarrhea, nausea, vomiting, etc. However, these side effects can usually be alleviated with appropriate medication management and supportive care. Doctors will adjust the drug dosage and treatment plan according to the patient's specific conditions to ensure the safety and effectiveness of the treatment.